← Eichor
Condition: Al Amyloidosis Al Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Al Amyloidosis Al

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Ch
Phase 1/Phase 2 · 23 location(s) · AbbVie · NCT06158854A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, an
Phase 2 · 5 location(s) · GlaxoSmithKline · NCT07224672Investigating the Pathogenic Role of N-glycosylation in AL Amyloidosis: Molecular Bases, Diagnosis, and Treatment
Phase N/A · 1 location(s) · Fondazione IRCCS Policlinico San Matteo di Pavia · NCT07448779Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagn
Phase 3 · 117 location(s) · SWOG Cancer Research Network · NCT06022939A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidos
Phase 1/Phase 2 · 20 location(s) · Regeneron Pharmaceuticals · NCT06292780Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial
Phase 2 · 2 location(s) · Mayo Clinic · NCT05898646A EUropean REgistry and Sample Sharing networK to Promote the Diagnosis and Management of Light Chain Amyloidosis (EUREK
Phase N/A · 6 location(s) · Fondazione IRCCS Policlinico San Matteo di Pavia · NCT06205953Safety and Efficacy of Metabolically Armed BCMA CAR-T Cells (Meta10-BCMA) in the Treatment of r/r Plasma Cell Neoplasms
EARLY_Phase 1 · 1 location(s) · Anhui Provincial Hospital · NCT07085559The Norwegian Immunotherapy in Multiple Myeloma Study
Phase N/A · 23 location(s) · St. Olavs Hospital · NCT06855121A Phase 1 Study of 99mTc-p5+14 in Healthy Volunteers and Patients With AL or ATTR Systemic Amyloidosis
Phase 1 · 1 location(s) · University of Tennessee Graduate School of Medicine · NCT05951816Prospective Study of Teclistamab in the Treatment of Systemic AL Amyloidosis
NA · 2 location(s) · Peking University People's Hospital · NCT06699394Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosi
Phase 1 · 9 location(s) · Gracell Biotechnologies (Shanghai) Co., Ltd. · NCT07250269Clinical Study for AL-CM
Phase N/A · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT04924998A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light
Phase 1 · 29 location(s) · Janssen Research & Development, LLC · NCT05652335Teclistamab in Previously Treated AL Amyloidosis
Phase 2 · 1 location(s) · Peking Union Medical College Hospital · NCT06935162Autologous BCMA-targeted CAR-T Cell Injection for Relapsed/Refractory Light Chain Amyloidosis
EARLY_Phase 1 · 1 location(s) · Beijing Boren Hospital · NCT07626476Daratumumab for Patients With Light Chain Amyloidosis
NA · 1 location(s) · Nanjing University School of Medicine · NCT06376214Bortezomib, Pomalidomide, Dexamethasone for Systemic AL Amyloidosis
Phase 2 · 1 location(s) · Jin Lu, MD · NCT06342466A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly
Phase 2 · 1 location(s) · Shanghai Zhongshan Hospital · NCT07638683A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloido
Phase 1/Phase 2 · 18 location(s) · Alexion Pharmaceuticals, Inc. · NCT07081646Teclistamab in Newly Diagnosed Mayo Stage IIIB AL Amyloidosis
Phase 2 · 1 location(s) · Peking Union Medical College Hospital · NCT07079423Evaluation of Skin Tests in Biotherapy Allergies
NA · 1 location(s) · University Hospital, Angers · NCT06971848DapagliFLOzin in Renal AL Amyloidosis (FLORAL)
Phase 2 · 1 location(s) · Barbara Ann Karmanos Cancer Institute · NCT06420167National Registry of Rare Kidney Diseases
Phase N/A · 1 location(s) · UK Kidney Association · NCT06065852Hungarian National Systemic Amyloidosis Registry
Phase N/A · 12 location(s) · Semmelweis University · NCT07689331Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource
Phase N/A · 1 location(s) · Ohio State University Comprehensive Cancer Center · NCT01408225BE.Amycon Biobank & Data Registry UZ Leuven
Phase N/A · 2 location(s) · Universitaire Ziekenhuizen KU Leuven · NCT07172243Teclistamab-Daratumumab in AL Amyloidosis
Phase 2 · 3 location(s) · Rajshekhar Chakraborty, MD · NCT07110844Sonrotoclax Plus Dexamethasone With or Without Daratumumab Regimen in Patients With t(11;14) Primary AL Amyloidosis
Phase 2 · 3 location(s) · Peking University People's Hospital · NCT07335887Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis
Phase 1/Phase 2 · 3 location(s) · University of Texas Southwestern Medical Center · NCT05145816
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.